Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mike McMullen, Bill Sullivan, Alessandro Borsatti, and More

Premium

Agilent announced this week that Mike McMullen, currently SVP of Agilent and president of the firm's Chemical Analysis Group, will become CEO of Agilent Technologies on March 18, 2015. Current CEO Bill Sullivan will remain an advisor to the firm through its fiscal year ending Oct. 31, 2015, when he will retire.

Agilent has also appointed Alessandro Borsatti to senior director of product marketing and scientific affairs. He has had various roles at Agilent since joining the company in February 2013. Before that, he was global business director of molecular diagnostics at PerkinElmer.


Thermo Fisher Scientific has appointed Andrea Califano, Arnold Levine, and Aviv Regev to its scientific advisory board.

Califano is founding chairman of the department of systems biology at Columbia University and he currently serves on th board of scientific advisors at the National Cancer Institute.

Levine is professor emeritus of systems biology at the Institute for Advanced Study and professor of pediatrics and of biochemistry with the Robert Wood Johnson Medical School at Rutgers, the State University of New Jersey.

Regev is a core member of the Broad Institute and an associate professor of biology at the Massachusetts Institute of Technology. She is also an investigator at the Howard Hughes Medical Institute.


Quanterix said this week that it has appointed Mark Roskey vice president and general manager, applications and reagents.

Roskey was previously vice president/general manager of the America's Sales and Service organization in PerkinElmer’s Life Science and Technologies division. Before that he held senior level commercial and technical positions at Caliper Life Sciences, which was acquired by PerkinElmer in 2011.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.